Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Oncology

Survivorship & Monitoring: Life After Initial Treatment

At a Glance

After initial ovarian cancer treatment, survivorship involves maintenance therapy and regular monitoring. Follow-up includes CA-125 blood tests, scans, and tracking physical symptoms to catch early signs of recurrence while preserving your quality of life.

Completing your initial round of surgery and chemotherapy is a significant milestone. As you transition into the survivorship phase, the focus shifts to maintaining your health, managing the side effects of maintenance therapy, and monitoring for any signs that the cancer may be returning. This period is often a “new normal” that requires both medical vigilance and emotional support.

Navigating Maintenance Therapy

Maintenance therapy is designed to keep the cancer at bay, but it often involves taking medication for months or even years [1]. While these drugs are generally well-tolerated, they do have specific side effects that your team will monitor closely.

Managing Side Effects & Dose Adjustments

It is important to know that dose reductions are a normal and common part of maintenance therapy [2]. If side effects become difficult, your doctor may lower your dose to find a “sweet spot” where the drug is still effective but your quality of life is maintained [2].

  • PARP Inhibitors (Niraparib, Olaparib): These can cause hematological issues like neutropenia (low white blood cell count), anemia (low red blood cells), and critically, thrombocytopenia (low platelets) [3][4]. Low platelets can increase your risk of bleeding and bruising, which your team will monitor via regular blood tests. You may also experience mild nausea or fatigue [5][6].
  • Bevacizumab (Avastin): This drug can lead to high blood pressure (hypertension), so regular monitoring at home is often recommended [7]. Critical Warning: Bevacizumab carries a Black Box Warning for a rare but life-threatening complication called Gastrointestinal (GI) Perforation (a hole in the stomach or intestine). If you experience sudden, severe abdominal pain, you must seek emergency medical care immediately [8].

Despite these potential issues, research shows that most patients on maintenance therapy maintain a high health-related quality of life compared to those not taking these medications [9][10].

The Monitoring Roadmap

Your medical team will use a combination of tools to watch for a recurrence.

  • CA-125 Monitoring: This blood test is a standard part of follow-up. While a rising CA-125 can be a very early warning sign—often appearing months before a tumor is visible on a scan—it is important to know that a rise in this marker alone does not always mean you need to start treatment immediately [11][12].
  • Imaging (CT, PET/CT): Scans provide a “picture” of what is happening inside your body. PET/CT scans are particularly useful for finding small areas of recurrence if your CA-125 is rising but a standard CT looks normal [13][14].
  • Physical Exams and Symptom Tracking: Regular check-ups with your oncologist are essential for identifying new symptoms that might not show up on a blood test [15][16]. While scans and bloodwork are helpful, you know your body best. Between appointments, you must report the following physical warning signs of recurrence:
    • Feeling full quickly or difficulty eating
    • Unusual, persistent abdominal bloating or swelling
    • New or worsening pelvic or abdominal pain
    • Changes in bowel habits (like unexplained constipation)

Addressing “Scanxiety”

The fear and distress that peak before a scheduled scan or while waiting for results is so common it has its own name: scanxiety [17]. This is a real and heavy psychological burden [18].

To help manage this anxiety:

  • Communicate: Ask your doctor exactly when and how you will receive your results [19].
  • Schedule Wisely: Try to book scans for earlier in the week to avoid waiting over a weekend for results [20].
  • Seek Support: Don’t hesitate to ask for a referral to a counselor or support group that specializes in cancer survivorship [21].

Surveillance is a marathon, not a sprint. By staying informed and vocal about your physical and emotional needs, you can navigate this phase with greater confidence and control.

Common questions in this guide

What is the schedule for CA-125 tests and imaging after ovarian cancer treatment?
Your oncologist will create a tailored monitoring schedule for your specific case. This typically involves regular CA-125 blood tests and periodic imaging, such as CT or PET/CT scans, to watch for any signs of recurrence.
What should I do if my CA-125 levels start to rise?
A rising CA-125 can be an early warning sign, but it does not always require immediate treatment. Your doctor will likely evaluate your physical symptoms and order imaging scans before deciding on the next steps.
Can the dose of my maintenance therapy be adjusted if I have bad side effects?
Yes, dose reductions are very common and normal during maintenance therapy. Your doctor can lower your dose to find a balance where the medication remains effective but the side effects are easier for you to manage.
What are the physical warning signs of an ovarian cancer recurrence?
Physical warning signs include feeling full quickly, unusual or persistent abdominal bloating, new pelvic or abdominal pain, and unexplained changes in bowel habits. You should report these symptoms to your medical team right away, even between regular check-ups.
What are the most common side effects of PARP inhibitors?
PARP inhibitors can lower your white blood cells, red blood cells, and platelets, which your team will monitor through regular blood tests. You might also experience mild nausea or fatigue while taking these medications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific schedule for CA-125 tests and imaging scans over the next two years?
  2. 2.If my CA-125 begins to rise but I have no symptoms, what will our next steps be?
  3. 3.What specific side effects (like high blood pressure or fatigue) should I report immediately while on maintenance therapy?
  4. 4.Are there dose adjustment options if the side effects of my maintenance drug become difficult to manage?
  5. 5.What resources are available through this clinic to help me manage 'scanxiety' or the emotional transition to survivorship?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    González-Martín A, Pothuri B, Vergote I, et al.

    The New England journal of medicine 2019; (381(25)):2391-2402 doi:10.1056/NEJMoa1910962.

    PMID: 31562799
  2. 2

    PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.

    Chelariu-Raicu A, Trillsch F, Burges A, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(5)):812-822 doi:10.1136/ijgc-2022-003990.

    PMID: 36707086
  3. 3

    Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer.

    Nishimyo K, Ishikawa KB, Aoki D, et al.

    Targeted oncology 2026; (21(2)):255-268 doi:10.1007/s11523-026-01202-7.

    PMID: 41723287
  4. 4

    Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.

    Hao J, Liu Y, Zhang T, et al.

    Critical reviews in oncology/hematology 2021; (157()):103145 doi:10.1016/j.critrevonc.2020.103145.

    PMID: 33254040
  5. 5

    Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002).

    Yamamoto S, Tsuchiya M, Iihara H, et al.

    Journal of Cancer 2024; (15(6)):1487-1497 doi:10.7150/jca.91675.

    PMID: 38370375
  6. 6

    Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.

    Eakin CM, Norton TJ, Monk BJ, Chase DM

    Gynecologic oncology 2020; (159(2)):581-587 doi:10.1016/j.ygyno.2020.08.016.

    PMID: 32972786
  7. 7

    Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies.

    Zhang M, Zhu J, Bao Y, et al.

    Frontiers in bioengineering and biotechnology 2025; (13()):1589841 doi:10.3389/fbioe.2025.1589841.

    PMID: 40474872
  8. 8

    The roles and limitations of bevacizumab in the treatment of ovarian cancer.

    Nakai H, Matsumura N

    International journal of clinical oncology 2022; (27(7)):1120-1126 doi:10.1007/s10147-022-02169-x.

    PMID: 35477830
  9. 9

    PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials.

    Wang Y, Ren F, Song Z, et al.

    Frontiers in oncology 2020; (10()):1204 doi:10.3389/fonc.2020.01204.

    PMID: 32850351
  10. 10

    Quality of life in ovarian cancer patients receiving maintenance therapy with bevacizumab versus PARPi: a network meta-analysis.

    Wu D, Wang Z, Yang W, et al.

    Expert review of anticancer therapy 2026; (26(6)):759-765 doi:10.1080/14737140.2025.2610267.

    PMID: 41457436
  11. 11

    The Average Time Gap Between CA-125 Tumor Marker Elevation and Confirmation of Recurrence in Epithelial Ovarian Cancer Patients at Princess Noorah Oncology Center, Jeddah, Saudi Arabia.

    Moharrag A, Yonbawi F, Bashawieh HH, et al.

    Cureus 2020; (12(8)):e9518 doi:10.7759/cureus.9518.

    PMID: 32884874
  12. 12

    Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer.

    Esselen KM, Cronin AM, Bixel K, et al.

    JAMA oncology 2016; (2(11)):1427-1433 doi:10.1001/jamaoncol.2016.1842.

    PMID: 27442965
  13. 13

    Diagnostic Value of PET/CT for Ovarian Cancer Recurrence or Metastasis in Postoperative Patients With Elevated Serum CA125 Levels: A Systematic Review and Meta-Analysis.

    Zou Z, Xia L, Tang S, et al.

    Cancer innovation 2025; (4(4)):e70015 doi:10.1002/cai2.70015.

    PMID: 40463490
  14. 14

    The Role of 18F-FDG PET/CT in Detecting Ovarian Cancer Recurrence in Patients with Elevated CA-125 Levels

    Cengiz A, Koç ZP, Özcan Kara P, Yürekli Y

    Molecular imaging and radionuclide therapy 2019; (28(1)):8-14 doi:10.4274/mirt.galenos.2018.00710.

    PMID: 30942056
  15. 15

    The utility of physical examination in ovarian cancer recurrence detection: a retrospective analysis informing virtual surveillance care.

    Janke MJ, Santiago S, Straubhar AM, Uppal S

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(7)):913-917 doi:10.1136/ijgc-2022-003506.

    PMID: 35675968
  16. 16

    Metabolic tumor burden predicts prognosis of ovarian cancer patients who receive platinum-based adjuvant chemotherapy.

    Yamamoto M, Tsujikawa T, Fujita Y, et al.

    Cancer science 2016; (107(4)):478-85 doi:10.1111/cas.12890.

    PMID: 26789906
  17. 17

    Smartphone-based Ecological Momentary Assessment to study "scanxiety" among Adolescent and Young Adult survivors of childhood cancer: A feasibility study.

    Heathcote LC, Cunningham SJ, Webster SN, et al.

    Psycho-oncology 2022; (31(8)):1322-1330 doi:10.1002/pon.5935.

    PMID: 35411626
  18. 18

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  19. 19

    "You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

    Derry-Vick H, Prigerson HG, Hahne J, et al.

    Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

    PMID: 41338711
  20. 20

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  21. 21

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702

This page explains ovarian cancer survivorship and monitoring for educational purposes. Your oncologist is the best source for managing your specific follow-up care and maintenance therapy.

Get notified when new evidence is published on Malignant epithelial tumor of ovary.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.